In addition to the direct effects of 2-DG on the cancer cells, systemically administered 2-DG together with focal irradiation of the tumor has been shown to activate antitumor immunity in the peripheral blood both in terms of increase in the levels of innate and adaptive cells and decrease in B cells, where a decrease in the CD4+ naïve T cells was paralleled by the increase in CD4+-activated T cells (258). Here, CD4 is linked to cancer.